Activation of k1-opioid receptor as a method for prevention of ischemic and reperfusion arrhythmias: Role of protein kinase C and KATP channels

Bulletin of Experimental Biology and Medicine

Volumn 143, Issue 2, 2007, Pages 187-190

  Lishmanov, A Yu ^a   Maslov, L N ^a   Lasukova, T V ^a   Crawford, D ^b   Wong, T M ^c  

^a Russian Academy of Medical Sciences   (Russian Federation)

^b Langford House   (United Kingdom)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Arrhythmias; Heart; Ischemia; Opioid receptors; Reperfusion

Indexed keywords

17 METHYLNALOXONE; 3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZENEACETAMIDE; ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; CHELERYTHRINE; GLIBENCLAMIDE; KAPPA OPIATE RECEPTOR AGONIST; KAPPA OPIATE RECEPTOR ANTAGONIST; NORBINALTORPHIMINE; POTASSIUM CHANNEL BLOCKING AGENT; PROTEIN KINASE C; ALKALOID; ANTIARRHYTHMIC AGENT; BENZOPHENANTHRIDINE DERIVATIVE; DRUG DERIVATIVE; KAPPA OPIATE RECEPTOR; NALTREXONE; OXYMORPHONE; POTASSIUM CHANNEL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIARRHYTHMIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CORONARY REPERFUSION; DRUG SELECTIVITY; ENZYME INHIBITION; HEART ARRHYTHMIA; HEART INFARCTION; HEART MUSCLE POTENTIAL; ISCHEMIC HEART DISEASE; MALE; NONHUMAN; RAT; RECEPTOR UPREGULATION; SARCOLEMMA; TREATMENT OUTCOME; ANIMAL; DRUG ANTAGONISM; DRUG POTENTIATION; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; REPERFUSION INJURY; WISTAR RAT;

3,4-DICHLORO-N-METHYL-N-(2-(1-PYRROLIDINYL)-CYCLOHEXYL)-BENZENEACETAMIDE, (TRANS)-ISOMER; ALKALOIDS; ANIMALS; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIAS, CARDIAC; BENZOPHENANTHRIDINES; GLYBURIDE; MALE; MYOCARDIAL REPERFUSION INJURY; NALTREXONE; OXYMORPHONE; POTASSIUM CHANNELS; PROTEIN KINASE C; RATS; RATS, WISTAR; RECEPTORS, OPIOID, KAPPA;

EID: 34547805219     PISSN: 00074888     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10517-007-0046-6     Document Type: Article

References (14)

1. L. N. Maslov, Yu. B. Lishmanov, N. V. Solenkova, et al., Eksper. Klin. Farmakol., 68, No. 1, 25-29 (2005).
2. S. D. Mikhailova, T. V. Vasil'eva, T. M. Semushkina, and G. I. Storazhikov, Byull. Eksp. Biol. Med., 129, No. 6, 34-36 (2000).
3. N. V. Solenkova, A. V. Krylatov, and V. Yu. Serebrov, Ibid., Suppl. 1, 23-25 (2001).
4. R. W. Behling and H. J. Malone, J. Mol. Cell. Cardiol., 27, No. 9, 1809-1817 (1995).
5. B. N. Dhawan, F. Cesselin, R. Raghubir, et al., Pharmacol. Rev., 48, No. 4, 567-592 (1996).
6. R. M. Fryer, Y. Wang, A. K. Hsu, and G. J. Gross, Am. J. Physiol. Heart Circ. Physiol., 280, No. 3, H1346-H1353 (2001).
7. G. J. Gross, Basic Res. Cardiol., 95, 280-284 (2000).
8. A. B. Hassouna, B. M. Matata, and M. Galinanes, Am. J. Physiol. Cell. Physiol., 287, No. 5, C1418-C1425 (2004).
9. Yu. B. Lishmanov, L. N. Maslov, and D. S. Ugdyzhekova, Clin. Exp. Pharmacol. Physiol., 26, 1325-1335 (1999).
10. W. F. Lubbe, T. Podzuweit, and L. H. Opie, J. Am. Coll. Cardiol., 19, No. 7, 1622-1633 (1992).
11. M. K. Pugsley, W. P. Penz, M. J. Walker, and T. M. Wong, Eur. J. Pharmacol., 212, No. 1, 15-19 (1992).
12. M. K. Pugsley, D. A. Saint, and M. J. Walker, Ibid., 261, No. 3, 303-309 (1994).
13. J. Russell, P. Bass, L. I. Goldberg, and H. Merz, Ibid., 78, No. 3, 255-261 (1982).
14. M. L. Zhuo, Y. Huang, D. P. Liu, and C. C. Liang, Int. J. Biochem. Cell. Biol., 37, No. 4, 751-764 (2005).